Beta-containing COVID-19 booster vaccine found to cross-neutralize

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2

COVID-19 booster after Omicron: Are 3rd or 4th shots necessary?

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Beta variant COVID-19 protein booster vaccine elicits durable cross- neutralization against SARS-CoV-2 variants in non-human primates

Coronavirus Calvert County Health Department

Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines - Mucosal Immunology

Latest on Omicron Variant and COVID-19 Vaccine Protection – NIH Director's Blog

China grants emergency use of new vaccines as it eases COVID-19 policy

Next-gen COVID vaccine to make persistent neutralizing antibodies

Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants

Moderna Says Studies Show Its Vaccine Is Effective Against The Delta Variant

Sanofi-GSK COVID-19 booster could compete against updated Moderna and Pfizer offerings - Drug Discovery and Development